• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Nestle Sa claimed ownership of 21,879,753 shares (SEC Form 3)

    10/2/24 8:15:23 AM ET
    $MCRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MCRB alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    NESTLE SA

    (Last) (First) (Middle)
    AVENUE NESTLE, 55

    (Street)
    CH-1800, VEVEY V8

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/30/2024
    3. Issuer Name and Ticker or Trading Symbol
    Seres Therapeutics, Inc. [ MCRB ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.001 21,879,753 I See Footnote(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    NESTLE SA

    (Last) (First) (Middle)
    AVENUE NESTLE, 55

    (Street)
    CH-1800, VEVEY V8

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Societe des Produits Nestle S.A.

    (Last) (First) (Middle)
    AVE NESTLE 55, CH-1800

    (Street)
    VEVEY V8

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. Held by Societe des Produits Nestle S.A. ("SPN"), a wholly-owned subsidiary of Nestle S.A. ("Nestle"). Nestle may be deemed to share voting and investment power with respect to the shares of Common Stock held by SPN.
    SOCIETE DES PRODUITS NESTLE S.A., By: /s/ Claudio Kuoni, Name: Claudio Kuoni, Title: Vice President 10/02/2024
    NESTLE S.A., By: /s/ Anna Mohl, Name: Anna Mohl, Title: Executive Vice President 10/02/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MCRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCRB

    DatePrice TargetRatingAnalyst
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    10/24/2024Neutral → Underweight
    JP Morgan
    6/26/2023$12.00Outperform
    Oppenheimer
    4/21/2023$7.00Neutral
    JP Morgan
    7/23/2021$42.00 → $29.00Buy
    Canaccord Genuity
    7/23/2021$30.00 → $16.00Buy
    Chardan Capital
    7/23/2021$36.00 → $18.00Outperform
    Oppenheimer
    7/23/2021$46.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MCRB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Seres Therapeutics Inc.

      SCHEDULE 13G/A - Seres Therapeutics, Inc. (0001609809) (Subject)

      6/6/25 10:03:48 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Seres Therapeutics Inc.

      S-8 - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 4:06:14 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Seres Therapeutics Inc.

      10-Q - Seres Therapeutics, Inc. (0001609809) (Filer)

      5/7/25 10:00:20 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care